Non-fucosylated Anti-Human CD38 (Daratumumab) Therapeutic Antibody (CAT#: BioBet-017ZP) Datasheet

CD38

platelet derived growth factor receptor alpha

This gene encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer or a heterodimer, composed of both platelet-derived growth factor receptor alpha and beta polypeptides. Studies suggest that this gene plays a role in organ development, wound healing, and tumor progression. Mutations in this gene have been associated with idiopathic hypereosinophilic syndrome, somatic and familial gastrointestinal stromal tumors, and a variety of other cancers.

Platelet Derived Growth Factor Receptor Alpha; Platelet-Derived Growth Factor Receptor, Alpha Polypeptide; Alpha-Type Platelet-Derived Growth Factor Receptor; Platelet-Derived Growth Factor Receptor 2; CD140 Antigen-Like Family Member A; CD140a Antigen; PDGF-R-Alpha; EC 2.7.10.1; PDGFR-2;

Membrane; Single-pass type II membrane protein

Diseases associated with CD38 include Richter's Syndrome and Prolymphocytic Leukemia.

Its related pathways are Calcium signaling pathway and Cell-type Dependent Selectivity of CCK2R Signaling.

Synthesizes the second messengers cyclic ADP-ribose and nicotinate-adenine dinucleotide phosphate, the former a second messenger for glucose-induced insulin secretion. Also has cADPr hydrolase activity. Also moonlights as a receptor in cells of the immune system.

Cancer antibody; Developmental Biology antibody; Immune System antibody; Metabolism antibody; Pro-B Cell Marker antibody; Pre-B Cell Marker antibody

1. Glycosylation at Asn100, Asn164, Asn209, and Asn219 2. Modification sites at PhosphoSitePlus 3. Glycosylation from GlyConnect

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

Daratumumab

Human

Human

Daratumumab is an anticancer drug that specifically targets CD38.

Multiple Myeloma (MM)

Not Available

Daratumumab is an immunoglobulin G1κ monoclonal antibody that specifically targets the CD38 antigen. CD38 is a transmembrane glycoprotein with many functions and is highly expressed in hematological malignancies, including multiple myeloma tumors. CD38 can regulate receptor-mediated adhesion, signaling, and cyclase and hydrolase activity. Daratumumab inhibits tumor cell growth and induces broad-spectrum apoptosis by binding to CD38 in a variety of mechanisms: Fc-mediated cross-linking, complement-dependent cytotoxicity, antibody-dependent cytotoxicity, and immune-dependent cell phagocytosis Lead tumor cell lysis.

Multiple Myeloma (MM)